View of Pathologic Response to Neoadjuvant Subcutaneous Fixed-Dose Pertuzumab–Trastuzumab (Phesgo®) and Chemotherapy in HER2-Positive Locally Advanced Breast Cancer: A Case Series and Literature Review

Return to Article Details Pathologic Response to Neoadjuvant Subcutaneous Fixed-Dose Pertuzumab–Trastuzumab (Phesgo®) and Chemotherapy in HER2-Positive Locally Advanced Breast Cancer: A Case Series and Literature Review Download Download PDF